Staud, Roland, Kizer, Taylor, Robinson, Michael E · Journal of pain research · 2017 · DOI
Researchers tested whether injecting a numbing medication (lidocaine) into muscles could help ME/CFS patients with fatigue and pain. Compared to a placebo injection, lidocaine injections did reduce fatigue more effectively, and both types of injections reduced pain, depression, and anxiety. This suggests that signals from muscles themselves may play a role in ME/CFS symptoms.
This study provides evidence that peripheral muscle signaling contributes to ME/CFS fatigue, a core symptom that remains poorly understood and difficult to treat. The finding that a local tissue intervention specifically reduces fatigue more than placebo opens new therapeutic avenues and supports the hypothesis that metaboreceptor dysfunction plays a role in disease pathophysiology.
This study does not establish that lidocaine injections are a practical clinical treatment—single injections into two muscles represent a limited intervention, and durability of effects is unknown. It does not prove that metaboreceptor dysfunction is the primary cause of ME/CFS, only that peripheral muscle signals contribute to fatigue. The lack of difference between lidocaine and saline for pain, depression, and anxiety suggests those improvements may be placebo effects rather than drug-specific effects.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →